FLT3/IRAK4 Inhibitor Crystal Forms for Stable AML Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current FLT3 inhibitors for acute myeloid leukemia (AML) exhibit limited efficacy, rapid disease relapse, and drug resistance due to target-dependent and non-target-dependent mutations, necessitating the development of more effective therapeutic strategies.
Innovation Solution
Development of crystal forms and salt forms of a five-membered-fused six-membered compound that inhibit FLT3 and/or IRAK4, targeting both kinases to potentially overcome drug resistance and improve patient prognosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If first-generation FLT3 inhibitors are used, then broad kinase inhibition is achieved, but efficacy is poor and toxicity is significantly increased
Solution Approach 1:
The patent applies local quality by designing a compound with specific structural features (five-membered ring fused to six-membered ring with particular substituent patterns) that enable selective inhibition of FLT3 and IRAK4 kinases while sparing other kinase families, thus achieving localized inhibition effect where broad inhibition was previously applied
2Adaptability or versatility
If first-generation FLT3 inhibitors are used, then broad kinase inhibition is achieved, but toxicity is significantly increased
Solution Approach 1:
The compound's specific molecular structure with defined substitution patterns on the fused ring system enables selective binding to FLT3 and IRAK4 active sites, reducing off-target effects on non-FLT3 kinases and thereby lowering toxicity while maintaining broad-spectrum anti-leukemic activity through dual kinase inhibition
3Measurement precision
If second-generation FLT3 inhibitors are used, then selectivity and activity are improved, but off-target effects still occur
Solution Approach 1:
The patent merges inhibition of two distinct kinases (FLT3 and IRAK4) into a single compound, leveraging their shared structural features to create a dual-inhibitor that achieves enhanced selectivity for leukemic cells while reducing off-target effects through coordinated inhibition of both targets
4Ease of operation
If FLT3 inhibitors are used as monotherapy, then treatment is simplified, but disease relapses rapidly with drug resistance emerging
Solution Approach 1:
The dual-inhibitor compound merges FLT3 and IRAK4 inhibition functions into one agent, enabling simplified monotherapy administration while preventing rapid relapse and drug resistance through simultaneous blockade of both kinases, thereby addressing the contradiction between treatment simplicity and therapeutic durability
5Reliability
If combination therapy with signaling pathway inhibitors is used, then non-target drug resistance is reduced, but the effect is still limited
Solution Approach 1:
The patent combines FLT3 and IRAK4 inhibition in a single compound, achieving synergistic anti-leukemic effects that exceed the sum of individual inhibitor effects, thereby overcoming the limited therapeutic benefit observed with conventional combination therapies while reducing resistance development
Data Source
AI summary
A crystal form and salt form of a five- and six-membered compound, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof are disclosed. Specifically, a crystal form and salt form of a five-membered-fused six-membered compound as shown in formula I, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof are disclosed. The crystal form and salt form of the compound have an inhibitory effect on FLT3 and/or IRAK4. The crystal form has a high single melt point, is thermodynamically stable, and has high crystallinity. The crystal form represents good physical and chemical stability under strong illumination, high temperature and high humidity conditions, and the crystal form has weak hygroscopicity.